Gsa Capital Partners LLP Cue Biopharma, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 149,798 shares of CUE stock, worth $146,802. This represents 0.01% of its overall portfolio holdings.
Number of Shares
149,798
Previous 291,663
48.64%
Holding current value
$146,802
Previous $221,000
26.24%
% of portfolio
0.01%
Previous 0.02%
Shares
17 transactions
Others Institutions Holding CUE
# of Institutions
57Shares Held
11.9MCall Options Held
22KPut Options Held
1.2K-
Bleichroeder LP New York, NY5MShares$4.9 Million1.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$2.02 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$741,6010.0% of portfolio
-
Geode Capital Management, LLC Boston, MA631KShares$618,6550.0% of portfolio
-
Robertson Stephens Wealth Management, LLC San Francisco, CA479KShares$468,9300.02% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $34.7M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...